EHA 2022 | MagnestisMM-1: elranatamab alone or with immunomodulatory agents in R/R multiple myeloma
Andrew Dalovisio
• 22 Jun 2022
Andrew Dalovisio, MD, Ochsner Medical Center, New Orleans, LA, discusses the results of the Phase I MagnetisMM-1 study aiming to characterize the safety, pharmacokinetics, pharmacodynamics, and efficacy of the BCMAxCD3 bispecific antibody elranatamab as a single agent or in combination with immunomodulatory agents in patients with relapsed/refractory (R/R) multiple myeloma (NCT03269136). The study reported promising efficacy, with the most common adverse events including neutropenia and cytokine release syndrome (CRS). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
